Brazil Anemia Drugs Market Analysis

Brazil Anemia Drugs Market Analysis


$ 3999

Brazil's Anemia drugs market was valued at $400 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.9% from 2022 to 2030 and will reach $850 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Cristalia Pharma, Ache, EMS Pharma, Eurofarma, BioLab Pharma, Roche, and Pfizer among others.

ID: IN10BRPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Nandini Shah

Buy Now

Brazil Anemia Drugs Market Executive Summary

Brazil's Anemia drugs market was valued at $400 Mn in 2022 and is estimated to expand at a CAGR of 9.9% from 2022-30 and will reach $850 Mn in 2030. Brazil is the largest country in South America, with a population of over 212 Mn people, and hence possesses the region's largest pharmaceutical market. Brazil has a publicly funded and government-run healthcare system that provides free and universal access to healthcare for the entire population, therefore its size alone provides enormous benefits to its residents. The Sistema nico de Sade (SUS) is the world's largest in terms of the user base, land covering, and linked treatment facilities. It is projected that Brazil's SUS presently spends roughly 10% of the country's GDP on healthcare, with that figure expected to climb to 12.6% by 2040.

Anemia is a medical disorder when the hemoglobin or red blood cell (RBC) level is below normal. Some of the most common indications and symptoms of Anemia include fatigue, shortness of breath, dizziness, and palpitations. Anemia is divided into three categories. Excessive blood loss, which can happen during childbirth, menstruation, or loss of RBCs due to protracted bleeding, causes Anemia. Anemia can be caused by inadequate intake of nutrients including vitamins and minerals, which can also reduce or impair the production of red blood cells. This type of Anemia includes conditions including sickle cell Anemia, iron deficiency Anemia, and vitamin deficiency Anemia. The term "hemolytic Anemia" refers to the breakdown of red blood cells (RBCs) as a result of RBC fragility and inability to withstand the usual stresses placed on the circulatory system. The market for drugs to treat Anemia is expected to grow fast during the period of forecasting.

Market Dynamics

Market Growth Drivers

Anemia is a significant health concern in Brazil, with an estimated 30% of the population affected by the condition. This high prevalence of anemia creates a large potential market for anemia. An aging population is more susceptible to anemia, due to the increased risk of chronic diseases and decreased ability to absorb nutrients from food. This is driving the growth of the anemia drugs market.  Brazil has a growing aging population, which is more susceptible to developing anemia. According to data from the United Nations, the proportion of people aged 65 and over in Brazil is projected to increase from 9.4% in 2020 to 25.5% in 2050. Brazil's Government has been investing in healthcare infrastructure, with a focus on expanding access to healthcare services and increasing healthcare spending. This increased investment is expected to drive demand for anemia drugs. The Brazilian regulatory agency, ANVISA, has been approving new drugs for the treatment of anemia. This is expected to increase competition in the market and provide patients with more treatment options. The use of biosimilars, which are lower-cost versions of biological drugs, is increasing in Brazil. This is expected to drive down the cost of anemia drugs and increase their affordability, which could lead to increased demand for these drugs.

According to the World bank the prevalence of anemia among children (6-59 months) was 12% and among women of reproductive age (15-49) was 16% in 2019. Anaemia is a severe global public health issue that adversely impacts children and pregnant women. According to the WHO, 42% of children under the age of five and 40% of pregnant women globally are anemic.

Market Restraints

Anemia drugs are expensive, and the high cost of treatment may be a barrier for patients, particularly those who do not have health insurance. According to a report by the Brazilian Ministry of Health, the cost of erythropoietin-stimulating agents (ESAs), the most common class of anemia drugs, can range from $58.5 to $967.5 per dose. This high cost could limit the accessibility of these drugs to many patients. The Brazilian government has implemented policies to control healthcare costs, including caps on drug prices and restrictions on drug reimbursement. These policies may limit the availability and affordability of anemia drugs, particularly for patients who are not covered by health insurance. Several major anemia drugs have lost or are set to lose patent protection in Brazil. This could lead to increased competition from lower-cost generics and biosimilars, which may limit the growth of the market for branded anemia drugs. Anemia drugs, particularly ESAs, have been associated with adverse effects such as hypertension, thromboembolism, and cardiovascular events. These adverse effects may limit the use of these drugs, particularly in patients with pre-existing cardiovascular disease.

Competitive Landscape

Key Players

  • Cristalia Pharma
  • Ache
  • EMS Pharma
  • Eurofarma
  • BioLab Pharma
  • Roche
  • Pfizer
  • Sanofi

Healthcare Policies and Regulatory Landscape

The Brazilian National Health System (SUS) is Brazil's publicly-funded healthcare system, which provides free or low-cost healthcare to the population. Anemia drugs, including ESAs, are included in the list of medications covered by SUS. The Brazilian Health Technology Assessment Committee (Comissão Nacional de Incorporação de Tecnologias, or CONITEC) is responsible for evaluating the clinical and economic effectiveness of health technologies, including anemia drugs, to determine whether they should be covered by SUS. The Brazilian Generic Drugs Program is a government initiative that aims to increase access to affordable medications, including anemia drugs, by offering them at lower prices through a network of participating pharmacies. The Brazilian Biosimilars Program is a government initiative that aims to promote the development and use of biosimilars, including biosimilar versions of ESAs used to treat anemia, in Brazil.

Reimbursement Scenario

Brazil has a two-tiered healthcare system that includes a public, universal healthcare system (Sistema Único de Saúde, or SUS) and a private healthcare sector. Reimbursement scenarios can differ greatly between the two, with SUS generally offering more limited coverage and reimbursement rates compared to private insurance plans. As the largest healthcare provider in Brazil, SUS is responsible for providing free or low-cost healthcare to the population. Many healthcare services and products, including medications, are covered by SUS. Healthcare providers, such as hospitals, clinics, and physicians, may have different reimbursement rates depending on the payer and the services provided. For example, hospitals that provide services to SUS patients may receive lower reimbursement rates than those that serve private insurance patients.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anemia Drugs Market Segmentation

By Type (Revenue, USD Bn)

  • Iron Deficiency
  • CKD (Chronic Kidney Disease)
  • Sickle Cell
  • Aplastic
  • Others

By Drugs

  • Dietary Supplements
  • Medicines

The types of nutritional supplements are further broken down into iron and vitamin supplements, among other categories, whilst the categories of medicines include antibiotics, hormones (erythropoietin), and chelation therapy (lead poisoning), among others.

By Distribution Channel (Revenue, USD Bn)

  • Hospital Pharmacy
  • Store Pharmacy
  • Online
  • Others

The distribution channel for anemia drugs in Brazil is complex and multifaceted. Pharmaceutical companies must work with a variety of stakeholders, including hospital and retail pharmacies, distributors, and regulatory authorities, to ensure that their products are effectively distributed to patients who need them.

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 12 October 2023
Updated by: Shivam Zalke

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up